Evidence map›Paper›PMID 36275648›Full record

ArticleFrontiers in immunology2022

Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections.

Tibor Bakacs, Konstantin Chumakov, Rifaat Safadi, Imre Kovesdi

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Masitinib Inhibits Hepatitis A Virus Replication.International journal of molecular sciences · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tibor BakacsDepartment of Probability, Alfred Renyi Institute of Mathematics; The Eötvös Loránd Research Network (ELKH), Budapest, Hungary.
Konstantin ChumakovOffice of Vaccines Research and Review, Food and Drug Administration, Silver Spring, MD, United States.
Rifaat SafadiHadassah Medical School, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Imre KovesdiUnleash Immuno Oncolytics, St. Louis, MO, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

RNA, Double-StrandedVirusesRNA, ViralRNA, Double-StrandedRNA, Viralattenuated virusescontrolled field trialsCOVID-19 vaccinedouble-stranded RNA (dsRNA)intentional viral coinfectioninterferon (IFN) systemmolnupiravir and paxlovidsuperinfection therapy (SIT)

Identifiers

PMID36275648
PMCPMC9584805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.